2024. Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 4 Years in the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials. SKIN The Journal of Cutaneous Medicine. 8, 4 (Jul. 2024), s407. DOI:https://doi.org/10.25251/skin.8.supp.407.